Recombinant antibody therapeutics: the impact of glycosylation on mechanisms of action.

More than twenty recombinant antibody molecules are now licensed for the treatment of a variety of cancers and chronic diseases. Initially, the attraction of antibodies was their specificity for target antigens; however, it is now appreciated that the downstream consequences of engaging antigen, after the formation of immune complexes, is crucial to clinical outcomes in vivo. This review introduces the structural and functional activities of the IgG class of recombinant antibodies, in vitro, and criteria that determine choice between the four subclasses. Importantly, we demonstrate that, although accounting for only 2-3% of antibody mass, glycosylation of the IgG-Fc is essential to the activation of downstream biologic mechanisms (effector functions). Additionally the precise structure of the attached oligosaccharide can influence biologic efficacy. These findings have led to cellular engineering to enable the production of selected glycoforms of antibody that are considered to be optimal for the disease indication to be treated.

[1]  C. Sautès-Fridman,et al.  The Structure of a Human Type III Fcγ Receptor in Complex with Fc* , 2001, The Journal of Biological Chemistry.

[2]  S. Fujimoto,et al.  Glycosylation and Placental Transport of Immunoglobulin G , 1996 .

[3]  S. Akilesh,et al.  FcRn: the neonatal Fc receptor comes of age , 2007, Nature Reviews Immunology.

[4]  James E. Bailey,et al.  Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity , 1999, Nature Biotechnology.

[5]  Li Yang,et al.  Structural characterization of N-linked oligosaccharides on monoclonal antibody cetuximab by the combination of orthogonal matrix-assisted laser desorption/ionization hybrid quadrupole-quadrupole time-of-flight tandem mass spectrometry and sequential enzymatic digestion. , 2007, Analytical biochemistry.

[6]  R J Harris,et al.  Heterogeneity of recombinant antibodies: linking structure to function. , 2005, Developments in biologicals.

[7]  T. Daniels,et al.  Characterisation of an engineered trastuzumab IgE antibody and effector cell mechanisms targeting HER2/neu-positive tumour cells , 2009, Cancer Immunology, Immunotherapy.

[8]  R. Dwek,et al.  Site-specific glycosylation of recombinant rat and human soluble CD4 variants expressed in Chinese hamster ovary cells. , 1993, The Journal of biological chemistry.

[9]  Robert A. Beckman,et al.  Antibody-Based Therapy for Solid Tumors , 2008, Cancer journal.

[10]  F. Perez,et al.  Meeting report & News from academia , 2008 .

[11]  P. Parren,et al.  Anti-Inflammatory Activity of Human IgG4 Antibodies by Dynamic Fab Arm Exchange , 2007, Science.

[12]  Quynh-Thu Le,et al.  Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. , 2008, The New England journal of medicine.

[13]  M. Basta.  Ambivalent effect of immunoglobulins on the complement system: activation versus inhibition. , 2008, Molecular immunology.

[14]  Leonard G Presta,et al.  Molecular engineering and design of therapeutic antibodies. , 2008, Current opinion in immunology.

[15]  J. Deisenhofer.  Crystallographic refinement and atomic models of a human Fc fragment and its complex with fragment B of protein A from Staphylococcus aureus at 2.9- and 2.8-A resolution. , 1981, Biochemistry.

[16]  M. Wadhwa,et al.  “Cytokine Storm” in the Phase I Trial of Monoclonal Antibody TGN1412: Better Understanding the Causes to Improve PreClinical Testing of Immunotherapeutics , 2007, The Journal of Immunology.

[17]  Johannes Kneer,et al.  Selective clearance of glycoforms of a complex glycoprotein pharmaceutical caused by terminal N-acetylglucosamine is similar in humans and cynomolgus monkeys. , 2007, Glycobiology.

[18]  R. Ghirlando,et al.  Glycosylation of human IgG-Fc: influences on structure revealed by differential scanning micro-calorimetry. , 1999, Immunology letters.

[19]  K. Shitara,et al.  The Absence of Fucose but Not the Presence of Galactose or Bisecting N-Acetylglucosamine of Human IgG1 Complex-type Oligosaccharides Shows the Critical Role of Enhancing Antibody-dependent Cellular Cytotoxicity* , 2003, The Journal of Biological Chemistry.

[20]  Jack Hoopes,et al.  Humanization of Yeast to Produce Complex Terminally Sialylated Glycoproteins , 2006, Science.

[21]  E. Friedländer,et al.  ErbB-directed immunotherapy: antibodies in current practice and promising new agents. , 2008, Immunology letters.

[22]  D. Burton,et al.  Human antibody effector function. , 1992, Advances in immunology.

[23]  S. Iida,et al.  The N-linked oligosaccharide at FcγRIIIa Asn-45: an inhibitory element for high FcγRIIIa binding affinity to IgG glycoforms lacking core fucosylation , 2008, Glycobiology.

[24]  J. Davies,et al.  Expression of GnTIII in a recombinant anti-CD20 CHO production cell line: Expression of antibodies with altered glycoforms leads to an increase in ADCC through higher affinity for FC gamma RIII. , 2001, Biotechnology and bioengineering.

[25]  Samuel Moser,et al.  Modulation of therapeutic antibody effector functions by glycosylation engineering: Influence of Golgi enzyme localization domain and co‐expression of heterologous β1, 4‐N‐acetylglucosaminyltransferase III and Golgi α‐mannosidase II , 2006, Biotechnology and bioengineering.

[26]  Roy Jefferis,et al.  Glycosylation as a strategy to improve antibody-based therapeutics , 2009, Nature Reviews Drug Discovery.

[27]  Thomas M. Dillon,et al.  Human IgG2 Antibody Disulfide Rearrangement in Vivo* , 2008, Journal of Biological Chemistry.

[28]  C. Szymanski,et al.  Campylobacter sugars sticking out. , 2008, Trends in microbiology.

[29]  T. Knöchel,et al.  Matuzumab binding to EGFR prevents the conformational rearrangement required for dimerization. , 2008, Cancer cell.

[30]  Stacey Ma,et al.  Characterization of a complex glycoprotein whose variable metabolic clearance in humans is dependent on terminal N-acetylglucosamine content. , 2008, Biologicals : journal of the International Association of Biological Standardization.

[31]  G. Weiner,et al.  Complement and cellular cytotoxicity in antibody therapy of cancer , 2008, Expert opinion on biological therapy.

[32]  D. Adu,et al.  Anti‐neutrophil cytoplasm antibody IgG subclasses in Wegener's granulomatosis: a possible pathogenic role for the IgG4 subclass , 2004, Clinical and experimental immunology.

[33]  Robert Huber,et al.  The 3.2-Å crystal structure of the human IgG1 Fc fragment–FcγRIII complex , 2000, Nature.

[34]  V. Ghetie,et al.  Interactions of immunoglobulins outside the antigen-combining site. , 2004, Advances in immunology.

[35]  R. Huber,et al.  Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity. , 2003, Journal of molecular biology.

[36]  David Passmore,et al.  Glycan optimization of a human monoclonal antibody in the aquatic plant Lemna minor , 2006, Nature Biotechnology.

[37]  Janice M. Reichert,et al.  Development trends for monoclonal antibody cancer therapeutics , 2007, Nature Reviews Drug Discovery.

[38]  L. Presta,et al.  Lack of Fucose on Human IgG1 N-Linked Oligosaccharide Improves Binding to Human FcγRIII and Antibody-dependent Cellular Toxicity* , 2002, The Journal of Biological Chemistry.

[39]  Shigeru Iida,et al.  Establishment of FUT8 knockout Chinese hamster ovary cells: An ideal host cell line for producing completely defucosylated antibodies with enhanced antibody‐dependent cellular cytotoxicity , 2004, Biotechnology and bioengineering.

[40]  R. Kircheis,et al.  Compensation of endogenous IgG mediated inhibition of antibody-dependent cellular cytotoxicity by glyco-engineering of therapeutic antibodies. , 2007, Molecular immunology.

[41]  M. Peipp,et al.  Effector mechanisms of therapeutic antibodies against ErbB receptors. , 2008, Current opinion in immunology.

[42]  T. Schneider-Merck,et al.  Effector Mechanisms of Recombinant IgA Antibodies against Epidermal Growth Factor Receptor1 , 2007, The Journal of Immunology.

[43]  Gary Walsh,et al.  Post-translational modifications in the context of therapeutic proteins , 2006, Nature Biotechnology.

[44]  Masakazu Toi,et al.  A Nonfucosylated Anti-HER2 Antibody Augments Antibody-Dependent Cellular Cytotoxicity in Breast Cancer Patients , 2007, Clinical Cancer Research.

[45]  Roy Jefferis,et al.  Antibody therapeutics: , 2007, Expert opinion on biological therapy.

[46]  Patricia W. Finn,et al.  Receptor-mediated Immunoglobulin G Transport Across Mucosal Barriers in Adult Life , 2002, The Journal of experimental medicine.

[47]  P. Carter.  Potent antibody therapeutics by design , 2006, Nature Reviews Immunology.

[48]  Shigeru Iida,et al.  IgG subclass-independent improvement of antibody-dependent cellular cytotoxicity by fucose removal from Asn297-linked oligosaccharides. , 2005, Journal of immunological methods.

[49]  A. Bitonti,et al.  Pulmonary delivery of an erythropoietin Fc fusion protein in non-human primates through an immunoglobulin transport pathway. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[50]  L. Simmons,et al.  Expression of full-length immunoglobulins in Escherichia coli: rapid and efficient production of aglycosylated antibodies. , 2002, Journal of immunological methods.

[51]  M. Aebi,et al.  Substrate specificity of bacterial oligosaccharyltransferase suggests a common transfer mechanism for the bacterial and eukaryotic systems. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[52]  U. Galili,et al.  The Galα1,3Galβ1,4GlcNAc-R (α-Gal) epitope: A carbohydrate of unique evolution and clinical relevance , 2008 .

[53]  G. Thibault,et al.  Recombinant therapeutic monoclonal antibodies: mechanisms of action in relation to structural and functional duality. , 2007, Critical reviews in oncology/hematology.

[54]  J. Ravetch,et al.  Fcγ receptors as regulators of immune responses , 2008, Nature Reviews Immunology.

[55]  Yoshiki Yamaguchi,et al.  Glycoform-dependent conformational alteration of the Fc region of human immunoglobulin G1 as revealed by NMR spectroscopy. , 2006, Biochimica et biophysica acta.